Neogene

San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry

Retrieved on: 
fredag, januari 12, 2024
Stanford University, DSM-IV codes, Overalls, Gene therapy, Flagship Pioneering, Biotechnology, Artificial intelligence, Neogene, CBER, Gene editing, Genome editing, Assistant professor, Therapy, Biological engineering, SAN, Humour, Harvard University, GenScript Biotech, Optimism, Safety, Patient, J. P. Morgan, AstraZeneca, Hope, GCT, Broad Institute, CBO, Process, Animal, Gene, ARCH Venture Partners, Multiple myeloma, Speech, Intellia Therapeutics, Development, Associate, Health, CRISPR, Intelligence, Courage, Research and development, Division, Conference, T cell, FDA, Eli Lilly and Company, SVP, Pharmaceutical industry

On January 10 this year, GenScript Biotech hosted the "Satellite Session" of the J.P. Morgan annual conference—the 2024 GenScript Biotech Global Forum in San Francisco.

Key Points: 
  • On January 10 this year, GenScript Biotech hosted the "Satellite Session" of the J.P. Morgan annual conference—the 2024 GenScript Biotech Global Forum in San Francisco.
  • GenScript Biotech is committed to building a high-quality platform for exchange and cooperation for global peers, driving the advancement of the cell and gene industry.
  • since the first global forum was held in 2020, GenScript Biotech has created numerous valuable opportunities for industry peers.
  • This grand event brought together the wisdom and strength of global elites in the biopharmaceutical industry, sparking a profound discourse on the future of GCT.

Titans Gather, Future Embarks: The GenScript Biotech Global Forum coinciding with the 2024 J.P. Morgan Healthcare Conference in San Francisco to Convene 20+ KOLs, Exploring Disruptive Transformations and Infinite Opportunities in GCT

Retrieved on: 
torsdag, december 14, 2023
Drug development, Eli Lilly and Company, Assistant, CBO, Partner (business rank), Senior, GenScript Biotech, Intellia Therapeutics, Gene editing, Entrepreneurship, Therapy, ARCH Venture Partners, Neogene, Biopharmaceutical, Flagship Pioneering, CSO, Value of life, FDA, Science, GCT, Forum, CRISPR, Speech, Life, Process, Medical device, Pharmaceutical industry, Nightclub, Fine chemical, Research

NANJING, China, Dec. 14, 2023 /PRNewswire/ -- Technological advancements continuously empower the life sciences. Gene and cell therapy (GCT), as breakthrough treatments, are turning the once-unreachable dream of curing many diseases into reality. Recently, the world's first CRISPR-Cas9 gene-editing therapy received market approval, marking another significant milestone in human biomedical progress.

Key Points: 
  • Gene and cell therapy (GCT), as breakthrough treatments, are turning the once-unreachable dream of curing many diseases into reality.
  • On January 10, 2024, the GenScript Biotech Global Forum will once again kick off in San Francisco.
  • Peter Marks, director of FDA's Center for Biologics Evaluation and Research (CBER) will make his keynote speech at the GenScript Biotech Global Forum.
  • On January 10, 2024, we cordially invite you to join us in San Francisco for the GenScript Biotech Global Forum.

Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
torsdag, november 9, 2023
Research, Bristol Myers Squibb, CAR, Lymphoma, Neogene, Patent, IPSC, CD19, G&A, Inflammation, GAAP, MBA, Differentiable function, R, BMS, ASH, Pharming, Century, Research and development, Interim, Ink, Autoimmunity, Cancer, Investment, Therapy, Patient, Administration, Life insurance, Pharmaceutical industry, Management, Cryptocurrency

PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) --  Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the third quarter ended September 30, 2023.

Key Points: 
  • - Ended third quarter 2023 with cash, cash equivalents, and investments of $284.3 million; Cash runway into 2026 -
    PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics , Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the third quarter ended September 30, 2023.
  • Greg Russotti, Interim Chief Executive Officer, Century Therapeutics added, “We continued to advance our Phase 1 ELiPSE-1 trial evaluating CNTY-101 in relapsed or refractory CD19 positive B-cell lymphomas.
  • He brings to Century over 20 years of broad-ranging global leadership experience across the healthcare industry, most recently serving as Chief Operating Officer at Neogene Therapeutics.
  • Cash Position: Cash, cash equivalents, and investments were $284.3 million as of September 30, 2023, as compared to $367.4 million as of December 31, 2022.

Breakthrough Properties to Develop New European Headquarters for Neogene Therapeutics

Retrieved on: 
torsdag, september 21, 2023
Carbon, CRISPR, Trinity, European Medicines Agency, CRISPR Therapeutics, Cancer, BREEAM, Research, AstraZeneca, PV, TCR, Science, Becton, Dickinson and Company headquarters, Biodiversity, Development, Isatis tinctoria, Innovation Park, City, Patient, UMC, August Kavel, Growth, Heat, UNStudio, Health, Therapy, Environment, Saint John's, BD, Airline, Pharmaceutical industry, Creative industries, Neogene, Breakthrough

AMSTERDAM, Sept. 21, 2023 /PRNewswire/ -- Breakthrough Properties, a premier global life sciences real estate developer, announced that it has reached an agreement with Neogene Therapeutics to develop its new European headquarters within the campus of the Amsterdam University Medical Center (Amsterdam UMC), one of Europe's leading medical institutions.

Key Points: 
  • Kavel F by Breakthrough (Kavel F) is destined to become one of the most sustainable laboratory environments in the world.
  • "Breakthrough is thrilled to support the Neogene team as it aims to bring the potential benefits of T cell receptor therapies to more patients with cancer," said Breakthrough Properties Chief Executive Officer and Co-Founder Dan Belldegrun.
  • "Kavel F is emblematic of Breakthrough Properties' mission to support cutting edge science by delivering high-quality, sustainable environments."
  • Prof. Dr. Hans van Goudoever, dean and vice chair of the executive board of Amsterdam UMC said, "Amsterdam UMC is thrilled to have Breakthrough Properties and Neogene as next-door partners.

Breakthrough Properties to Develop New European Headquarters for Neogene Therapeutics

Retrieved on: 
torsdag, september 21, 2023
Carbon, CRISPR, Trinity, European Medicines Agency, CRISPR Therapeutics, Cancer, BREEAM, Research, AstraZeneca, PV, TCR, Science, Becton, Dickinson and Company headquarters, Biodiversity, Development, Isatis tinctoria, Innovation Park, City, Patient, UMC, August Kavel, Growth, Heat, UNStudio, Health, Therapy, Environment, Saint John's, BD, Airline, Pharmaceutical industry, Creative industries, Neogene, Breakthrough

AMSTERDAM, Sept. 21, 2023 /PRNewswire/ -- Breakthrough Properties, a premier global life sciences real estate developer, announced that it has reached an agreement with Neogene Therapeutics to develop its new European headquarters within the campus of the Amsterdam University Medical Center (Amsterdam UMC), one of Europe's leading medical institutions.

Key Points: 
  • Kavel F by Breakthrough (Kavel F) is destined to become one of the most sustainable laboratory environments in the world.
  • "Breakthrough is thrilled to support the Neogene team as it aims to bring the potential benefits of T cell receptor therapies to more patients with cancer," said Breakthrough Properties Chief Executive Officer and Co-Founder Dan Belldegrun.
  • "Kavel F is emblematic of Breakthrough Properties' mission to support cutting edge science by delivering high-quality, sustainable environments."
  • Prof. Dr. Hans van Goudoever, dean and vice chair of the executive board of Amsterdam UMC said, "Amsterdam UMC is thrilled to have Breakthrough Properties and Neogene as next-door partners.

Day One Reports First Quarter 2023 Financial Results and Corporate Progress

Retrieved on: 
måndag, maj 1, 2023
Rituximab, Bevacizumab, Society, Drug development, Capecitabine, New Drug Application, Roche, Neogene, Food and Drug Administration, Clinical trial, NDA, Cancer, MAPK, SNO, MBA, MEK, CMO, CCO, Doctor of Philosophy, ASCO, Research and development, Pakistan Society of Neuro-Oncology, Goldman Sachs, Development, American Society of Clinical Oncology, MD, Patient, Investment, Pediatrics, Roivant Sciences, Annual general meeting, Webcast, FDA, Conference, Day One, ASPHO, D, Pharmaceutical industry, Nursing, Medical imaging, Video game, Genentech, Research

BRISBANE, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its first quarter 2023 financial results and highlighted recent corporate achievements.

Key Points: 
  • The company remains in position to initiate the submission of the NDA as early as the second quarter of 2023.
  • R&D Expenses: Research and development expenses were $27.8 million for the first quarter of 2023 compared to $15.0 million for the first quarter of 2022.
  • G&A Expenses: General and administrative expenses were $18.0 million for the first quarter of 2023 compared to $12.7 million for the first quarter of 2022.
  • Day One will present two posters at the 2023 American Society of Pediatric Oncology/Hematology (ASPHO) Conference May 10-13, 2023, focused on the pLGG burden of illness and healthcare utilization data.

Shoreline Biosciences Announces Appointment of Mauro P. Avanzi, M.D., Ph.D., As Chief Medical Officer

Retrieved on: 
tisdag, februari 21, 2023
TCR, Ink, Shore, IPSC, Executive, IMac, Publication, Cell, USP, Patient, Drug, Doctor of Philosophy, Kite Pharma, Research, Memorial Sloan Kettering Cancer Center, Growth, SAN, AstraZeneca, Cancer, Pharmaceutical industry, Neogene, EU

SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms, today announced the appointment of Mauro P. Avanzi, M.D., Ph.D. as Chief Medical Officer.

Key Points: 
  • SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms, today announced the appointment of Mauro P. Avanzi, M.D., Ph.D. as Chief Medical Officer.
  • In his new role, Dr. Avanzi will be responsible for leading and expanding Shoreline's clinical portfolio and will serve as a key member of its Executive team.
  • "We are extremely pleased that Mauro is joining Shoreline at such a pivotal time in the growth of our company.
  • at Campinas Medical School (Puc) in Brazil and completed an internal medicine residency and hematology/oncology fellowship at the São Paulo University (USP).

Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics

Retrieved on: 
tisdag, november 29, 2022
Growth, AstraZeneca, Doctor of Philosophy, Kite Pharma, Private equity, Netherlands Cancer Institute, TPG, TP53, Cell, KRAS, Partnership, Patient, Do Meu Jeito, Arm, Polaris Partners, Protein, Investment, Cancer, TCR, Entrepreneurship, Acquisition, Pharmaceutical industry, Vaccine, Management, Medical imaging, MD, Neogene, EU

Paris, France, November 29th2022 - Jeito Capital ("Jeito"), the largest fully independent international private equity firm dedicated to healthcare and biopharma, is pleased to announce the realization of its investment in Neogene Therapeutics, Inc. (Neogene Therapeutics or Neogene) to AstraZeneca a global, science-led biopharmaceutical company.

Key Points: 
  • Paris, France, November 29th2022 - Jeito Capital ("Jeito"), the largest fully independent international private equity firm dedicated to healthcare and biopharma, is pleased to announce the realization of its investment in Neogene Therapeutics, Inc. (Neogene Therapeutics or Neogene) to AstraZeneca a global, science-led biopharmaceutical company.
  • Neogene is a global clinical-stage company pioneering the discovery, development, and manufacturing of next-generation T cell receptor therapies (TCR-Ts).
  • Jeito co-led Neogenes $110 million Series A financing marking the first investment since the launch of the fund.
  • Since Jeitos investment, Neogene has become a clinical stage company, and expanded both its pipeline of next-generation TCR-Ts and its manufacturing capabilities.

AstraZeneca to Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy

Retrieved on: 
tisdag, november 29, 2022
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, AstraZeneca, Doctor of Philosophy, Science, TPG, Netherlands Cancer Institute, TP53, Cell, KRAS, Partnership, Therapy, MBA, Patient, Arm, Polaris Partners, Protein, Kite Pharma, Investment, Cancer, TCR, Entrepreneurship, Acquisition, Principal, Pharmaceutical industry, Medical imaging, Vaccine, Management, Healthcare, MD, Neogene, EU

Most current cell therapy approaches in oncology focus on modifying the immune systems T cells to recognize proteins expressed on the surface of cancer cells.

Key Points: 
  • Most current cell therapy approaches in oncology focus on modifying the immune systems T cells to recognize proteins expressed on the surface of cancer cells.
  • In contrast, TCR-Ts can recognize intracellular targets, including cancer-specific mutations, thereby potentially unlocking targets previously inaccessible using cell therapies.
  • Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: This acquisition represents a unique opportunity to bring innovative science and leading experts in T-cell receptor biology and cell therapy manufacturing together with our internal oncology cell therapy team, unlocking new ways to target cancer.
  • AstraZeneca is building a cell therapy portfolio that aims to empower and equip the immune systems T cells, to more effectively fight cancer.

Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors

Retrieved on: 
tisdag, maj 10, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Gene, Population, NKI, Neoplasm, Safety, TP53, Probability, CTA, Patient, TCR, Netherlands Cancer Institute, Partnership, Adult, HLA, Research, Growth, KRAS, Therapy, Pharmaceutical industry, Neogene

The Phase 1 study will enroll adult patients with various types of advanced solid tumors in partnership with the Netherlands Cancer Institute (NKI), an internationally acclaimed research institute and leading cancer clinic.

Key Points: 
  • The Phase 1 study will enroll adult patients with various types of advanced solid tumors in partnership with the Netherlands Cancer Institute (NKI), an internationally acclaimed research institute and leading cancer clinic.
  • NT-125 is an investigational, autologous, fully-individualized, multi-specific TCR therapy targeting neoantigens for the treatment of advanced solid tumors.
  • Patients with recurrent and metastatic solid tumors currently have a high unmet need and limited effective treatment options.
  • Neogene is a global biotechnology company focused on discovering, developing, and manufacturing novel, transformative TCR therapies targeting neoantigens in solid cancers.